A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment

Authors:

Abstract
Lung cancer is the most widespread malignancy globally and the leading cause of cancer‐related deaths, highlighting the need for innovative treatments. Herein, a novel inhaled vaccine carrier is presented by modifying dextran (Dex) with N , N ‐dimethylethylenediamine (DMEN) and 4‐(bromomethyl)phenylboronic acid (PBA) (Dex–DMEN–PBA, DDP). The optimized DDP demonstrates a potent adjuvant effect in promoting dendritic cell (DC) maturation by multiple signaling pathways. Moreover, the nanovaccine (DDP/Lewis lung carcinoma (LLC)) forms through electrostatic interactions between DDP and protein antigens derived from LLC cells. Upon inhalation, it induces DC maturation, T cell activation, and germinal center B cell activation in the thoracic lymph node. In the mouse model, the inhaled DDP/LLC nanovaccine displays impressive prophylactic effects against lung cancer, with 50% of mice alive after six months and 33% surviving a subsequent challenge, indicating strong long‐term immune memory. Remarkably, it surpasses subcutaneous vaccination, particularly in activating germinal center B cells and follicular helper T (Tfh) cells, and upregulating tissue‐resident memory T (T RM ) cells in the lung. This self‐adjuvant nanovaccine effectively prevents tumor growth and induces robust immune memory, offering valuable insight for treating lung cancer and related diseases.
Funding Information
  • National Natural Science Foundation of China (52450010, 52325106, 52271248)
  • Program of Shanghai Academic Research Leader (23XD1402900)
  • Natural Science Foundation of Jiangsu Province (BK20240040)

This publication has 53 references indexed in Scilit: